Analysts expect over 2020 rising revenue UCB

On Monday the Belgian company UCB will publish its past quarters results. For this year UCB's revenue will be around 5,19 billion euros. This is according to the average of the analysts' estimates. This is slightly more than 2019's revenue of 4,91 billion euros.

Historical revenues and results UCB plus estimates 2020


The analysts expect for 2020 a net profit of 907 million euros. The majority of the analysts expects for this year a profit per share of 4,86 euros. Based on this the price/earnings-ratio is 22,82.

For this year the analysts expect a dividend of 1,23 euros per share. The dividend yield is then 1,11 percent. The average dividend yield of the pharmaceutical companies is a limited 0,21 percent.

Newest target prices around 123 euros

The most recent recommendations for the pharmaceutical company are from Sanford C. Bernstein & Co, Goldman Sachs and Bryan Garnier.

Based on the current number of shares UCB's market capitalization equals 20,95 billion euros. The UCB stock was the past 12 months quite volatile. Since last July the stock is even 58 percent higher. This year the stock price moved between 60 and 114 euro.

Historical stock prices UCB

financial analysis ucb

Click here for dividend UCB. At 9.21 the stock trades 1,67 percent lower at 110,9 euros. Nieuwsdienst: +31 084-0032-842

Copyright B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.